Canada markets closed

Novartis AG (NVS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
89.42+0.77 (+0.87%)
At close: 04:00PM EDT
89.50 +0.08 (+0.09%)
After hours: 07:44PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close88.65
Bid0.00 x 800
Ask0.00 x 1000
Day's Range88.42 - 89.45
52 Week Range79.09 - 95.17
Avg. Volume2,605,355
Market Cap197.851B
Beta (5Y Monthly)0.48
PE Ratio (TTM)8.33
Earnings DateN/A
Forward Dividend & Yield3.33 (3.72%)
Ex-Dividend DateMar 08, 2022
1y Target EstN/A
  • GlobeNewswire

    Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions

    Positive opinion could expand the role of Cosentyx® (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EUSafety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indicationsSince its initial approval, Cosentyx has a proven sustained efficacy profile across several systemic inflammatory conditions and has treated more than 700,000 patients worldwide 1-11 Ba

  • GlobeNewswire

    Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer

    Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new biomarker analysis of Piqray® plus fulvestrantData for Tafinlar® + Mekinist® in pediatric patients with BRAF V600 low-grade glioma to be featured in ASCO official press briefingFirst release of 96-week data on Scemblix® in Ph+ CML in chronic phase patients previously treated with ≥2 prior tyrosine kinase i

  • GlobeNewswire

    New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients

    With further follow-up of MONALEESA-3, Kisqali plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for postmenopausal women living with HR+/HER2- aBC1 When used 1L, Kisqali plus fulvestrant added nearly 16 months of survival benefit to the lives of patients compared to fulvestrant alone, with a 33% relative reduction in the risk of death1 Kisqali is the only CDK4/6 inhibitor-fulvestrant combination to demonstrat